Sign In
Buy ANTX
$4.20
+0.130 (+3.19%)
At Close: Jun 03, 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
10:36am, Tuesday, 21'st May 2024
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
04:01pm, Tuesday, 14'th May 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
04:10pm, Thursday, 28'th Mar 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
08:17pm, Monday, 11'th Mar 2024
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics, Inc. (ANTX)
04:45pm, Tuesday, 05'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possible
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
10:30am, Sunday, 03'rd Mar 2024
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possi
AN2 Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ANTX
01:30pm, Tuesday, 27'th Feb 2024
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AN2 Therapeutics, Inc. ("AN2 Therapeutics") (NASDAQ:ANTX) concerning possi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
10:00am, Saturday, 24'th Feb 2024
NEW YORK , Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised to c
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
06:20pm, Thursday, 15'th Feb 2024
NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ("AN2" or the "Company") (NASDAQ: ANTX). Such investors are advised
LOS ANGELES, CA / ACCESSWIRE / February 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AN2 Therapeut
AN2 Therapeutics to pause lung disease study enrollment
06:56am, Monday, 12'th Feb 2024
AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-e
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas
